Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Fostering Synthetic Biology standardisation through international collaboration (BioRoboost)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: Coordination and support actions
Countries involved: Spain,Germany,Germany,Spain,Austria,Spain,Italy,Singapore,Switzerland,Switzerland,Norway,Belgium,Greece,China,Slovenia,France,United States,Denmark,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Japan
Call: Standardisation in Synthetic Biology (CSA) (H2020-NMBP-BIO-CSA-2018, 2018)
Start date: 2018-10-01
End date: 2021-09-30
Duration (months): 36.0
Total project cost (EUR): 2177587.5
EU funding (EUR): 1998787.5
Participants: 28
Project status: CLOSED

Synthetic Biology is an engineering research field aiming at (re)designing biological circuits for applied purposes. As any other engineering field, it strongly relies on the use of well-defined, universal and robust standard components. The outstanding success of synthetic biology in the last years should not hide the difficulties in defining biological standards. There are both historical and technical difficulties to reach that ambitious goal. On the former: the crossroad nature of synthetic biology involving mainly biologists/biotechnologists and engineers, whose views on the standardisation of living beings tend to differ; among the latter: the intrinsic features of live (mutation, emergent properties, fitness biasses, variability and, of course, evolution). In BIOROBOOST we propose to finally overcome cultural issues and to dramatically advance in solving technical difficulties by i) gathering the most relevant stakeholders of all the aspects of standardisation in biology in Europe in a co-creation scenario; ii) by empirically testing cultural (lab-centric) standardisation practices and by promoting a consensus conceptual and technical redefinition of biological standards; and, finally, iii) by fostering a realistic and flexible toolbox of standard biological parts, including a reduced set of specialised chassis for specific applications as well as a renewed conceptual framework to inform policy makers, scientific and other societal actors.

Keywords: standards,international coordination
Defining the antithrombin measurand: role of proteoforms in harmonisation of diagnostic tests in thrombosis (HarmonizATforms)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Netherlands
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-05-01
End date: 2021-04-30
Duration (months): 24.0
Total project cost (EUR): 187572.48
EU funding (EUR): 187572.48
Participants: 1
Project status: CLOSED

Current medical tests for antithrombin deficiency generally measure the overall activity, being blind for the actual proteoforms of AT that contribute to the test. To ensure accurate test results, a traceability chain needs to be in place, which requires the accurate definition of the exact analyte to be measured. I hypothesize that an in-depth understanding of the pathological molecular proteoforms of antithrombin (AT) will allow for the identification of clinically relevant proteoforms and enable test harmonization, resulting in a test with a well-defined clinical outcome that are actionable by clinicians. Mass spectrometry (MS) is an emerging technique in the field of clinical chemistry, which is well suited for the detection of proteoform characteristics and outperforms testing methods based on immunoassays. Therefore my aims are 1. To develop a mass spectrometry based test for the quantification of individual characteristics of molecular proteoforms of AT. 2. Analytically validate the developed method according to clinical chemistry procedures, and 3. Assess the role of MS based test for the standardization of AT tests. I am a passionate scientist with a strong background in the development of MS-based tests for proteins. I plan to perform the project in collaboration with my supervisor, who has large experience in medical test development and the ECAT foundation, who is specialized in proficiency testing of AT and test harmonization. This project will allow me to obtain skills and experience to oversee and develop a clinical test from biomarker discover to test evaluation and implementation, specifically in the niche of thrombosis and haemostasis, as well as the transferable skills required to eventually establish my own independent research group.

Keywords: thrombosis and homeostasis,antithrombin,quantitative clinical chemistrthrombosis and homeostasis,quantitative clinical chemistry proteomics,relative quantitation,proteoforms,test harmonisation
Antibody-based IL-7R targeted therapies (IL7RsignaTHER)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Portugal
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2020-01-01
End date: 2021-12-31
Duration (months): 24.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Acute lymphoblastic leukemia (ALL), a highly aggressive hematological cancer, is the most frequent childhood malignancy and the second most common acute leukemia in adults. The use of risk-adjusted multi-agent intensive chemotherapy has led to a remarkable improvement in treatment outcome of pediatric cases, with more than 80% of children with ALL being alive and disease-free at 5 years. However, a significant number of relapses still occur, whose prognosis is dismal, and the intensive regimens used are often associated with long-term, severe complications. In adults, the scenario is considerably worse: only 30–40% of the cases achieve long-term remission. Therefore, there is an obvious unmet need, and a major challenge, to develop novel, more efficient therapeutic strategies that specifically target the leukemic cells, minimize the detrimental side effects associated with conventional therapies and improve overall treatment outcome. Based on exciting and robust preliminary data from our ERC Consolidator Grant IL7sigNETure (CoG-648455), we now propose to explore the dependence of ALL cells on IL-7/IL-7R-mediated signaling and the broad expression of IL-7R on the surface of ALL cells to develop and commercialize novel monoclonal antibody-based biopharmaceuticals that we will generate targeting the IL-7/IL-7R axis for treatment of this malignancy. Our innovative therapeutic strategies have significant market potential that extends beyond ALL. Other possible indications include other lymphoid malignancies (Hodgkin's lymphoma, peripheral T-cell lymphoma, chronic lymphocytic leukemia), solid cancers with ectopic expression of IL-7R (including melanoma, breast, lung, bladder and colorectal cancer, or glioblastoma), and autoimmune and chronic inflammatory diseases (diabetes, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease) in which the IL-7/IL-7R axis plays a pathological role.

Keywords: cancer,leukemia,t all,il 7r,targeted therapies,novel antibody based biopharmaceuticals
Photomechanical writing of cell functions (PHOTOMECH)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Condensed matter physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Germany
Call: ERC CONSOLIDATOR GRANTS (ERC-2020-COG, 2020)
Start date: 2021-05-01
End date: 2026-04-30
Duration (months): 60.0
Total project cost (EUR): 2433445.0
EU funding (EUR): 2433445.0
Participants: 1
Project status: SIGNED

Generating artificial organs and tissues from stem cells would revolutionize regenerative medicine and open the door to controllable, biology-based robotics. These systems require a physical understanding of cells, specifically their dynamic and adaptive responses to external forces. This “mechanotransduction” is already known to control important cellular functions, and even stem cell differentiation. With the project proposed here, I plan to bring our quantitative understanding of force-controlled cell functions to a new level by a challenging and novel photomechanical cell stimulation approach. It will combine new materials containing photoswitchable molecules with a complex optical system employing intense laser light pulses. By pulsing the laser, we can apply controllable force stimuli on cells through a conformational change of the photoswitchable molecules. I hypothesize that cell functions, such as adhesion, migration and differentiation, have a huge systematic dependency on frequency, duration, history, and intensity of the force stimuli. Importantly, the method I propose applies forces to cells solely via light and does not require genetic modifications. Using this novel strategy for photomechanical stimulation of cellular proteins, we will be able to collect previously unobtainable physical information within cells on multiple size scales, from the single molecule to tissue level. Using the laser like a pen, we will be able for the first time to write cell functions in 3D, imitating the growth of the cellular scaffolds in living creatures: a completely new means of photomechanically controlling multicellular structures. Ultimately, the tools and materials we study in this interdisciplinary project will allow for the writing of multicellular structures in vitro and in vivo by force-induced mechanotransduction in stem cells. It will lead to a paradigm-shift in many fields, from biophysics to regenerative medicine, synthetic biology and biohybrid robotics.

Keywords: cellular biophysics,mechanotransduction,biomaterials,responsive materials,stem cell differentiation
Motor Condition Monitor (MCM)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Action type: SME instrument
Countries involved: Portugal
Call: Stimulating the innovation potential of SMEs for a low carbon and efficient energy system (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-08-01
End date: 2018-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

In Industrial Units, electrical motors are the heart of every activity. The global electric motor market is expected to reach a value of 113.280€ million by 2019. Considering maintenance and operational schedule, predictive tools are a critical asset rather than reactive or preventive maintenance to avoid serious losses or safety problems. If a motor suddenly stops, the industrial factory manager must decide if the motor should be replaced or rewound. This brings huge losses to the company especially if the motor is critical, creating heavily downtime losses. On the other side, electric motors are responsible for approximately 40% of the total electrical energy generated worldwide, and represent the most important component in the industry energy consumption and 75% of global CO2 industrial emissions. As typically electric motors operate at poor efficiency, there is a great potential to improve energy efficiency in this sector. MCM allows to continuously monitoring electric motors, even the ones that are submerged in liquids, decreasing the downtime and operating costs in industrial facilities, increasing this way productivity and equipment’s lifetime. Additionality it brings safety benefits since a catastrophic motor failure can result in serious security hazards. MCM enables an accurate prediction of malfunctions in electric motors and improvement their efficient operation. This allows for a reduction of approximately 70% of the repairing costs and 85% of the equipment’s downtime and the efficiency levels can be increased by 15%, resulting in an additional reduction of the operating costs. The gains achieved through the electric motors continuous monitoring and the consequent optimization measure, have also an important role in the reduction of the high energy consumption in the industry sector. Therefore the key bywords are reliability and efficiency. Imagine that a machine could warn you about a possible malfunction and poor efficiency: MCM is the solution.

Keywords: predictive maintenance,continuous condition monitoring,energy efficiency,industrial motors,factory monitoring,cost reduction,real time monitoring,downtime reduction
Development of a compatible nanoparticle based rapid and sensitive diagnostic platform for microbial infections (RapidDiag)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: United Kingdom
Call: European SME innovation Associate - pilot (H2020-INNOSUP-02-2016, 2016)
Start date: 2017-09-01
End date: 2018-08-31
Duration (months): 12.0
Total project cost (EUR): 70187.5
EU funding (EUR): 70187.5
Participants: 1
Project status: CLOSED

LIG Biowise Ltd specialises in the development of targeted nanodrugs and targeted nanodiagnostic systems. The company is now developing a next generation rapid diagnostic system for use by healthcare staff to quickly determine whether medical symptoms are a viral infection or bacterial infection. Many infectious diseases present with similar symptoms and it can be difficult to correctly diagnose and treat a patient without further diagnostic investigation. Infectious diseases are one of the major cases of global morbidity and mortality, resulting in 16.2% of all deaths per year. The majority of these infectious diseases are a result of viral or bacterial pathogens. It is estimated that in the UK alone, over 10 million needless antibiotic prescriptions are written each year. This number includes prescriptions incorrectly given to patients suffering from viral infections. This is not only a waste of financial resources, but also leads to the development of drug resistant bacteria strains. This trend has been repeated worldwide, meaning that antibiotics are losing their effectiveness at an increasing rate and antibiotic resistance has become a worldwide problem. A diagnostic kit, such as the product proposed by LIG Biowise, will save millions of euros in costs associated with the over prescription of antibiotics for viral infections and lead to reductions in the number of drug resistant bacteria. LIG Biowise’s rapid medical diagnostic kit will give healthcare staff a rapid diagnosis, while remaining technologically simple, have minimal training requirements and will not require expensive instrumentation. The SME Innovation Associate will play a crucial role in helping LIG Biowise reach this goal. They will also undertake a 12-month training programme, including; a mentoring scheme with academic and industrial leaders, opportunities to attend conferences, and full participation in EU core training programme.

Keywords: nanoparticle,diagnostic
Commercial feasibility of an integrated soft robotic system for industrial handling (SoftHandler)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Systems and communication engineering
Panel description: Electrical, electronic, communication, optical and systems engineering
Countries involved: Italy,Italy
Call: ERC Proof of Concept Grant (ERC-2018-PoC, 2018)
Start date: 2019-03-01
End date: 2020-08-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 71750.0
Participants: 2
Project status: CLOSED

Picking and placing objects that are orderly presented to a robot is a task that can be easily performed by current robots. However, grasping and manipulating objects randomly placed in an unstructured environment remains one of the hardest challenges for robots. Examples of complex picking industrial applications include (i) bin picking for part feeding, (ii) raw food handling and (iii) waste sorting for recycling. Within the "SoftHandler" ERC Proof of Concept project, we propose to develop new industrial-grade systems, comprised of end-effectors based on the "SoftHands" technology, integrated with a novel manipulator, for automated picking and placing of objects of heterogeneous dimension, shape, weight, position and strength. The Proof of Concept project will be focused on building a commercially viable prototype, and demonstrating it in real-world scenarios.

Keywords: robotics,unstructured environment,material handling,soft manipulator
Fully RoHS Compliant Infrared Light Emitting Diodes Based on Novel Lead-free Quantum Dots (INFLED)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-04-01
End date: 2024-03-31
Duration (months): 24.0
Total project cost (EUR): 171473.28
EU funding (EUR): 171473.28
Participants: 1
Project status: SIGNED

Infrared light-emitting diodes (IR-LEDs) serve a broad range of applications including fiber-optic communications, night vision as well as clinical diagnosis and biomedical imaging. Within the family of nanomaterials, colloidal semiconductor quantum dots (QDs) offer exceptional promises for IR-LEDs due to their unique optical properties and low-cost solution-processability. So far, state-of-the-art QD IR-LEDs are based on lead-containing QDs, which has been severely restricted by the environmental directives e.g. EU’s “Restriction of Hazardous Substances” (RoHS). In fact, current challenges of IR-LED technology are to identify and develop novel and efficient lead-free QDs. INFLED aims at demonstrating the first RoHS-compliant and efficient QD IR-LED based on innovative and environmentally friendly material design and device engineering. The project targets the most efficient heavy metal-free infrared QD using a novel synthesis technique as well as rationally nanoengineering at material level. Furthermore, the resultant design at device level will lead to low trap state density, high solid-state quantum efficiency and thereby efficient LEDs. Hence, the key objectives of this proposal are: i) a novel QD synthesis method; ii) material design at nanocrystalline level; iii) LED device engineering at supra-nanocrystalline level. INFLED is at the crossroad of chemistry, physics and engineering, and therefore is expected to attract significant attention from different disciplines along with offering new insights toward next-generation infrared and quantum network technology.

Keywords: light emitting diode,infrared,quantum dot,nanocrystal,colloidal
AI-based acoustic condition monitoring of industrial machinery (Motorlisten)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Netherlands
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-08-01
End date: 2019-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Before the break, mechanical objects emit unusual noises - machines talk and grumble. These grumbles are warning signals that a fault is developing, which if left untreated can lead to motor failure and unscheduled downtime in the facility. At costs of up to €300,000+ per hour, unplanned downtime is a very big problem for industrial plants and utilities alike. OneWatt has invented a non-invasive predictive maintenance system, combining an auditory sensor ("EARS"), which picks up a machine's grumbles, with an AI machine-learning algorithm. The system, developed to TRL 7, can detect and predict physical faults in machinery - and can tell maintenance staff not only that a fault is developing but exactly how, where and when the fault will happen. The system emulates an expert mechanic, who can identify faults just by hearing motor sounds, but because it uses AI and an infinitely larger data set than a human can experience, it is much more reliable than any human could be - and scalable. This will optimize maintainance work and minimize downtime, a big priority for industrial companies and utilities, who will be the initial customer targets. The potential market is global, worth an estimated € 3bn+. OneWatt's system will help companies implement a much more targeted, cost-effective "smart maintenance" strategy and become part of Industry 4.0 technology and the "Industrial Internet of Things". OneWatt's system will also be very attractive for other industries that have assets that emit acoustic signals, such as gearboxes or valves. Future target markets will include wind turbines, heat pumps and water distribution equipment. The objectives of the Phase 1 feasibility study are (i) to establish the parameters required to reach 99.99% accuracy; quantify targets and establish methodologies to achieve longer asset lifetime and lower energy consumption and (ii) to analyse the commercial potential of the technology among industrial manufacturers and utilities.

Keywords: acoustics,condition monitoring,industrial motors,artificial intelligence,cloud computing,smart maintenance,predictive maintenance,machine learning algorithms,acoustic sensors